Scientific Advisory Board
Nitin Parekh, Ph.D. has served in senior a management level with DSM, Chemie Linz, Upjohn (Pharmacia-Pfizer), Monsanto (The NutraSweet company), Hoechst, Boehringer Mannheim and Knoll AG. In addition, he has extensive experience in strategic development working with Biotech, Start-up and emerging pharma companies. Some of the companies Nitin has concluded deals with include Genzyme, Cubist, Myriad, Gilead, Ilex, OSI Pharma and more. Dr. Parekh is an advisor on translation of scientific content to the commercial environment.
Matthew DeLisa, Ph.D., Scientific Advisor and inventor of ProCode, Associate Professor in the Department of Chemical and Molecular Engineering, Cornell University is the recipient of numerous awards including recognition of one of the top 35 investigators under the age of 35 by the MIT Technology Review. Dr. DeLisa is the developer of the initial discoveries that resulted in ProCode. His research interests include integrating engineering design principles with protein biochemistry, microbiology and modern biotechnology to create microorganisms with new or improved protein machinery for solving problems in human health that cannot be solved using natural systems.
Robert F. Garry, Ph.D. Professor of Microbiology and Immunology at Tulane University School of Medicine. His research has focused on a number of aspects of viral pathogenesis, including seminal work on viral cellular entry mechanisms. He has made numerous seminal discoveries in infectious diseases pathology that are critical to our understanding of these diseases as well as their link to autoimmune disease. Dr. Garry manages a large international consortium of academic and industry researchers who are developing modern diagnostic assays and elucidating the immunopathogenesis of Lassa fever and other severe viral illnesses.